Trials (Apr 2024)

Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters

  • Estee P. M. Lau,
  • Matthew Ing,
  • Sona Vekaria,
  • Ai Ling Tan,
  • Chloe Charlesworth,
  • Edward Fysh,
  • Ranjan Shrestha,
  • Elaine L. C. Yap,
  • Nicola A. Smith,
  • Benjamin C. H. Kwan,
  • Tajalli Saghaie,
  • Bapti Roy,
  • John Goddard,
  • Sanjeevan Muruganandan,
  • Arash Badiei,
  • Phan Nguyen,
  • Mohamed Faisal Abdul Hamid,
  • Vineeth George,
  • Deirdre Fitzgerald,
  • Nick Maskell,
  • David Feller-Kopman,
  • Kevin Murray,
  • Aron Chakera,
  • Y C Gary Lee

DOI
https://doi.org/10.1186/s13063-024-08065-1
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Malignant pleural effusion (MPE) is a debilitating condition as it commonly causes disabling breathlessness and impairs quality of life (QoL). Indwelling pleural catheter (IPC) offers an effective alternative for the management of MPE. However, IPC-related infections remain a significant concern and there are currently no long-term strategies for their prevention. The Australasian Malignant PLeural Effusion (AMPLE)-4 trial is a multicentre randomised trial that evaluates the use of topical mupirocin prophylaxis (vs no mupirocin) to reduce catheter-related infections in patients with MPE treated with an IPC. Methods A pragmatic, multi-centre, open-labelled, randomised trial. Eligible patients with MPE and an IPC will be randomised 1:1 to either regular topical mupirocin prophylaxis or no mupirocin (standard care). For the interventional arm, topical mupirocin will be applied around the IPC exit-site after each drainage, at least twice weekly. Weekly follow-up via phone calls or in person will be conducted for up to 6 months. The primary outcome is the percentage of patients who develop an IPC-related (pleural, skin, or tract) infection between the time of catheter insertion and end of follow-up period. Secondary outcomes include analyses of infection (types and episodes), hospitalisation days, health economics, adverse events, and survival. Subject to interim analyses, the trial will recruit up to 418 participants. Discussion Results from this trial will determine the efficacy of mupirocin prophylaxis in patients who require IPC for MPE. It will provide data on infection rates, microbiology, and potentially infection pathways associated with IPC-related infections. Ethics and dissemination Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee has approved the study (RGS0000005920). Results will be published in peer-reviewed journals and presented at scientific conferences. Trial registration Australia New Zealand Clinical Trial Registry ACTRN12623000253606. Registered on 9 March 2023.

Keywords